['arthritis, rheumatoid']
['placebo']

        Inclusion Criteria:

          -  Have a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening

          -  Have moderately to severely active RA with at least 8 of 68 tender joints and 6 of 66
             swollen joints, at screening and at baseline

          -  Have previous or current treatment with methotrexate (MTX) and are considered
             intolerant to MTX, and/or are considered inappropriate for treatment with MTX,
             (including MTX-naïve subjects for whom it is inappropriate to administer MTX) and/or
             an inadequate responder to methotrexate

          -  Must not have received MTX or any other non-biologic DMARD including but not limited
             to sulfasalazine, hydroxychloroquine, chloroquine, and bucillamine for at least 2
             weeks prior to the first administration of the study agent

          -  C-reactive protein >= 10.00 mg/L or erythrocyte sedimentation rate >=28 mm/hr at
             screening

        Exclusion Criteria:

          -  Has Functional Class IV as defined by the ACR Classification of Functional Status in
             Rheumatoid Arthritis

          -  Has ever received biologic therapy for RA, including but not limited to the following:
             TNF-alpha inhibitors, tocilizumab, rituximab, anakinra, abatacept

          -  Has ever used tofacitinib therapy or any other JAK inhibitor

          -  Has received intra-articular, intramuscular, or IV corticosteroids for RA, including
             adrenocorticotrophic hormone during the 4 weeks prior to first study agent
             administration

          -  Has received leflunomide within 24 months before the first study agent administration
             and has not undergone a drug elimination procedure, unless the M1 metabolite is
             measured and is undetectable
      